Efficacy of 51Cr-EDTA clearence to tailor a carboplatin therapeutic regimen in ovarian cancer patients

Anticancer Research

Volumn 19, Issue 6 C, 1999, Pages 5587-5591

  Martino, Gaetano ^a   Frusciante, Vincenzo ^a   Varraso, Antonio ^a   Barbano, Filippo ^a   Capotorto, Annamaria ^a   Dicembrino, Franca ^a   Petruzzelli, Francesco ^a   Rubini, G ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Calvert formula; Carboplatin; Glomerular filtration rate

Indexed keywords

CARBOPLATIN; EDETATE CHROMIUM CR 51; PACLITAXEL; ANTINEOPLASTIC AGENT; CHELATING AGENT; CHROMIUM; EDETIC ACID;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; OVARY CANCER; PATIENT COMPLIANCE; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; OVARY TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHELATING AGENTS; CHROMIUM RADIOISOTOPES; EDETIC ACID; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0033233431     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Parkin DM, Laarke & Muir CS: Estimates of the worldwidefrequency of sixteen major cancers in 1980. Int J Cancer 41: 184-197, 1988.
2. Calvert AH, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum (II). Cancer Chemoter Pharmacol 9: 140, 1982.
3. Muggia FM: Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol16: 7, 1989.
4. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7(11): 1748-1756, 1989.
5. Sorensen BT, Strömgren A, Jakobsen P, et al: Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother and Pharmacol 28: 397-401, 1941.
6. Van Warmerdam LJC, Rodenhuis S, ten Bokkel Huinink WW, et al: The use of the Calvert formula to determine the optimal carboplatin dosage J Cancer Res Clin Oncol 121: 478-486, 1995.
7. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and Cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334: 1-6, 1996.
8. Ten Bokkel Huinic WW, Veenof CHN, Helmerhost ThJM, et al: Carboplatin (C) and Paclitaxel (Taxol) in patient with advanced ovarian cancer: a dose finding study. Proc of ASCO 1995, NA 746.
9. Ozols RF: Carboplatin and Paclitaxel (Taxolo®) for treatment of advanced ovarian cancer. Int J Gynecol Cancer 4 (Suppl 1): 13-17, 1994
10. Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J clin Lab Invest 30: 271-274, 1972
11. 51Cr-EDTA. Clin Sci 37: 169-180, 1969.
12. Bröchner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J clin Lab Invest 36: 35-43, 1976.
13. Egorin MJ, Van Echo DA, Tipping SJ, et al: Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44: 5432-5438, 1984.
14. Egorin MJ, Van Echo DA, Olman EA, et al: Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutane-dicarboxilatoplatinum. Cancer Res 45: 6502-6506, 1985.
15. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Nat Cancer Inst 87: 573-580, 1995.
16. Russell CD, Dubovsky EV: Measurement of renal function with radionuclides. J Nucl Med 30: 2053-2057, 1989.
17. 2) and Carboplatin (AUC = 7) in patients with advanced inoperable epithelial ovarian cancer :preliminary toxicity data. Ann Oncol 5 (Suppl 5): NA 514 , P. 204, 1994.
18. Jodrell DI, Egorin MJ, Canetta RM, et al: Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520-528, 1992.
19. Calvert AH, Lind MJ, Ghazal-Aswad S, et al: Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer : a phase 1 dose-intensity escalation study. Semin Oncol 12: 1-6, 1994.
20. Crawford J, O'Rourke MA: Vinorelbine (Navelbine)/Carboplatin combination therapy : dose intensification with granulocyte colony-stimulating factor. Semin Oncol 21(Suppl. 10): 73-78, 1994.
21. Langer CJ, Leighton JC, Comis RL: Paclitaxel and carboplatin incombination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13: 1860-1870, 1995.